Semaglutide
GLP-1 Receptor Agonist
Half-life: ~7 days (SC injection)
Research Profile
Relative research assessments — educational reference only.
Target Receptors
Buying peptides in Bali?
See community-reported Bali price ranges for Semaglutide and 9 other compounds — clinic menus, WhatsApp quotes and import realities.
Open the Bali Price Index →Critical Research Warning
Research chemicals are not for human consumption. Rodent studies have indicated a potential risk for thyroid C-cell tumors; contraindicated in individuals with a family history of Medullary Thyroid Carcinoma (MTC).
"A long-acting GLP-1 analog distinguished by its C18 fatty diacid chain, enabling albumin binding and a half-life of ~7 days. One of the most clinically studied peptides in modern metabolic research."
Full Description
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist structurally homologous to human GLP-1 with approximately 94% sequence identity. Its C-18 fatty diacid side chain enables non-covalent binding to albumin, dramatically extending its half-life to ~7 days compared to native GLP-1 (~2 min). Research demonstrates potent insulinotropic effects, glucagon suppression, delayed gastric emptying, and significant reductions in body weight via hypothalamic appetite regulation.
Mechanism of Action
Activates GLP-1 receptors in the pancreatic β-cells, hypothalamus, brainstem, and gut. Increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via CNS pathways.
Reported Benefits
- • Significant reduction in body weight in clinical models
- • Improved glycemic control via enhanced insulin secretion
- • Cardiovascular risk reduction in specific populations
- • Appetite suppression through hypothalamic regulation
Potential Side Effects
- • Gastrointestinal distress (nausea, vomiting, diarrhea)
- • Potential risk of thyroid C-cell tumors (based on rodent models)
- • Pancreatitis risk in predisposed individuals
- • Gallbladder disease (cholelithiasis)
Frequently Asked Questions
How is Semaglutide used for weight loss?▼
What kind of results are typical in research studies?▼
How often does it need to be administered?▼
For Research Reference Only
Not medical advice. Peptides may be regulated or restricted in your jurisdiction.
References
- 1.Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease. PubMed (2026). Cavender MA, et al.. pubmed.ncbi.nlm.nih.gov/42552888/ ↑
- 2.Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice. PubMed (2026). Sawada M, et al.. pubmed.ncbi.nlm.nih.gov/42552642/ ↑
- 3.Semaglutide-Induced Sarcopenia via GLP-1R-mTOR-Satellite Cells Axis and Muscle-Glucose Feedback Loop Potentially Leading to Refractory Hyperglycemia in Type 2 Diabetes: A Case-Driven Hypothesis. PubMed (2026). Ahmed A, et al.. pubmed.ncbi.nlm.nih.gov/42545324/ ↑
- 4.Development and validation of a sensitive HPLC-MS/MS method for the analysis of semaglutide in human plasma. PubMed (2026). Tudan C, et al.. pubmed.ncbi.nlm.nih.gov/42544568/ ↑
Where to Source Semaglutide
27 vendors listed · ranked most → least trusted · not an endorsement
Rankings are community-derived. Always independently verify COAs before any research use. PeptidePlaza is not affiliated with any vendor.
Sell Semaglutide on PeptidePlaza
Get listed as a verified vendor and reach researchers directly.
Related Research Articles
From the PeptidePlaza research blog.